

KS127 Anti Human CD59 (HRF20) Monoclonal Antibody (Clone No. YUK1)		Application	
Primary Source	HGNC:1689	WB	Not tested
Type	Monoclonal	IHC	Not tested
Immunogen	Human Cancer Cell Line	ICC	Not tested
Raised in	Mouse	ELISA	Not tested
Myeloma	P3U1	FCM	5.0-10.0 µg/mL
Clone number	YUK1	Neutralization	Not tested
Isotype	IgG1, κ	IP	5.0-10.0 µg/mL
Source	Serum Free Medium		
Purification notes	ProteinG		
Cross Reactivity	Not yet tested in other species.		
Concentration	0.25 mg/mL		
Contents (Volume)	50 µg (200 µL/vial)		
Label	Unlabeled		
Buffer	PBS [containing 2 % Block Ace as a stabilizer, 0.1 %Proclin as a bacteriostat]		
Storage	Store below -20 . Once thawed, store at 4 . Repeated freeze-thaw cycles should be avoided.		

Note

CD59 (also known as HRF20: 20KDa-Homologous restriction factor) is an about 20 kDa glycoprotein and member of membrane-bound complement-regulatory protein (CRP), and prevents formation of the membrane attack complex (MAC) in the terminal stages of complement activation. CRPs inhibit complement-mediated killing of host cells by host complement. It has been also showed that p53 regulates cellular resistance to complement lysis through enhanced expression of CD59.

CRPs are often elevated in malignancy, and enable tumor cells to escape from complement-dependent cytotoxicity. Therefore, expression, overexpression, or loss of these molecules may function as markers of tumor progression and prognosis.

This antibody is specific to human CD59 and will be useful for FCM, immunoprecipitation.

CD59 (HRF20: 20KDa-Homologous restriction factor) は約 20 kDa の糖タンパク質で、膜結合型補体調節因子 (CRP: complement-regulatory protein) の一つであり、補体形成の最終段階である膜損傷複合体 (MAC: membrane attack complex) の形成を阻害し補体による自己細胞溶解を防いでいます。

癌抑制遺伝子、p53 が CD59 の発現を促進し、細胞溶解を阻害することが明らかとなっており、悪性腫瘍において CRPs が増加し、補体依存性細胞障害活性 (CDC: complement-dependent cytotoxicity) から腫瘍細胞を保護していることが示されています。CRPs の発現、過剰発現、欠損は癌の進行や診断のマーカーとなることが期待されています。

本抗体はヒトCD59 に特異的な抗体であり、FCM、免疫沈降に使用できます。

Reference

- | | | |
|---|---|--|
| 1 | Björge L. et al.: Expression and function of CD59 on colonic adenocarcinoma cells. | Eur J Immunol.
1994 Jul;24(7):1597-603. |
| 2 | Chen S. et al.: CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma | Cancer Res.
2000 Jun 1;60(11):3013-8. |
| 3 | Madjd Z. et al.: Loss of CD59 expression in breast tumours correlates with poor survival. | J Pathol.
2003 Aug;200(5):633-9. |
| 4 | Donev RM. et al.: p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. | Cancer Res.
2006 Feb 15;66(4):2451-8. |
| 5 | Ellison BS. et al.: Complement susceptibility in glutamine deprived breast cancer cells. | Cell Div.
2007 Jul 11;2:20. |

WARNING AND PRECAUTION

取り扱い上の注意

- Not for diagnostic use. The safety and efficacy of product in diagnostic or other clinical uses has not been established.
- Harmful by inhalation, in contact with skin and if swallowed. Do not breathe dust. Avoid contact with skin and eyes.
- If contact with skin and eyes, wash all affected areas with large volume of water. If inhaled remove to fresh air. In severe case obtain medical attention.
- Wash hand thoroughly after handling the product.
- Do not use this product if container is broken or some contaminants are detected.
- When preserving the product. Close the container, ensure it does not fall aside or down.
- Dispose of the container and expired reagents in accordance with federal, state and local government regulations.
- Do not use the container and accessories of the product for other purpose.

この添付文書をよく読んでから使用して下さい。

- 本品は研究用試薬であり、医薬品その他の目的にはご使用になれません。
- 取り扱い中は皮膚、粘膜、着衣に触れたり、目に入らないように適切な措置を行って下さい。
- 試薬が誤って目や口に入った場合には、水で十分に洗い流すなどの応急処置を行い、必要があれば医師の手当を受けて下さい。
- 取り扱い後は手洗いを十分に行ってください。
- 容器の破損、異物混入等異常が認められた物は使用しないで下さい。
- 試薬を保管する場合は、蓋をし、転倒落下防止を確実にし、指定の貯蔵方法で保管して下さい。
- 使用後の容器は、廃棄物に関する規定に従って処理して下さい。
- 容器、付属品等の他目的への転用は保証できません。